Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2015 Apr 1;33(10):1098-100.
doi: 10.1200/JCO.2014.60.1419. Epub 2015 Mar 2.

Does degree of androgen suppression matter in hormone-sensitive prostate cancer?

Daniel L Suzman  1 , Emmanuel S Antonarakis  2
Affiliations
Editorial

Does degree of androgen suppression matter in hormone-sensitive prostate cancer?

Daniel L Suzman et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at www.jco.org.

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

DANIEL L. SUZMAN

No relationship to disclose

EMMANUEL S. ANTONARAKIS

Honoraria: Sanofi, Dendreon, Medivation, Janssen Biotech

Consulting or Advisory Role: Sanofi, Dendreon, Medivation, Janssen Biotech

Research Funding: Janssen Biotech (Inst), Johnson & Johnson (Inst), Sanofi (Inst), Dendreon (Inst), Aragon Pharmaceuticals (Inst), Exelixis (Inst), Millennium Pharmaceuticals (Inst), Genentech (Inst), Novartis (Inst)

Travel, Accommodations, Expenses: Sanofi, Dendreon, Medivation

Comment on

References

    1. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148–1159. - PMC - PubMed
    1. Klotz L, O’Callaghan C, Ding K, et al. Nadir tesosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: A secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol. 2015;33:1151–1156. - PMC - PubMed
    1. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983–992. - PubMed
    1. Ryan CJ, Smith MR, Fizazi K, et al. Final overall survival (OS) analysis of COU-AA-302, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer patients without prior chemotherapy. Ann Oncol. 2014;25:iv255–iv279.
    1. Crook JM, O’Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012;367:895–903. - PMC - PubMed

MeSH terms